MELD Score Calculator
Model for End-Stage Liver Disease — calculates both MELD-Na (UNOS standard since 2016) and MELD 3.0 (OPTN standard since 2023) for liver transplant prioritisation, 90-day mortality estimation, and assessment of end-stage liver disease severity.
Calculate MELD-Na & MELD 3.0
Enter the laboratory values below. This calculator computes both the MELD-Na (current UNOS allocation score) and MELD 3.0 (adopted by OPTN in January 2023, which adds sex and albumin). For an assessment of hepatic functional reserve in cirrhosis, see the Child-Pugh Score calculator.
The MELD score is a continuous scale — there are no fixed “categories” in transplant allocation. Organs are offered to the patient with the highest MELD in the compatible donor pool. MELD exception points may be granted for conditions where the score underestimates disease severity (e.g., hepatocellular carcinoma, hepatopulmonary syndrome). Allocation policies vary by country and region.
Understanding the MELD Score
The MELD score was originally developed by Malinchoc et al. (2000) to predict survival following transjugular intrahepatic portosystemic shunt (TIPS) procedures. Kamath et al. (2001) validated it as a predictor of 3-month mortality in patients with end-stage liver disease, and it was adopted by the United Network for Organ Sharing (UNOS) in 2002 to replace the Child-Turcotte-Pugh score for liver transplant allocation in the United States.
The fundamental principle is “sickest first” — patients with the highest MELD scores receive the highest priority for available donor organs. This replaced the prior time-based system, which prioritised waiting time rather than disease severity, and which was associated with significant mortality on the waiting list for the sickest patients.
MELD-Na Formula (UNOS 2016)
Step 1 — Original MELD:
MELD(i) = 10 × [0.957 × ln(Cr) + 0.378 × ln(Bili) + 1.120 × ln(INR) + 0.643]
Step 2 — Add sodium:
MELD-Na = MELD(i) + 1.32 × (137 − Na) − [0.033 × MELD(i) × (137 − Na)]
Bounds: Na 125–137, labs min 1.0, Cr max 4.0 (or 4.0 if dialysed). Range: 6–40.
MELD 3.0 Formula (OPTN 2023)
MELD 3.0 = 1.33 (if female) + 4.56 × ln(Bili) + 0.82 × (137 − Na) − 0.24 × (137 − Na) × ln(Bili) + 9.09 × ln(INR) + 11.14 × ln(Cr) + 1.85 × (3.5 − Alb) − 1.83 × (3.5 − Alb) × ln(Cr) + 6
Bounds: Na 125–137, Alb 1.5–3.5, labs min 1.0, Cr max 3.0 (or 3.0 if dialysed). Range: 6–40.
Why MELD 3.0? The original MELD and MELD-Na systematically underestimated disease severity in women, because creatinine — a key MELD component — is typically lower in women at equivalent levels of renal dysfunction due to lower muscle mass. MELD 3.0 addresses this disparity by adding sex and albumin as variables, improving fairness in organ allocation across sex and reducing waitlist mortality among female candidates.
Score Interpretation & Mortality Estimates
The MELD score was originally validated as a predictor of 3-month mortality without transplantation. The mortality estimates below are approximate and apply to patients with cirrhosis who are not transplanted. Actual survival varies by aetiology, presence of complications (variceal bleeding, ascites, HCC), and response to treatment.
| MELD Score | 3-Month Mortality (Without Transplant) | Clinical Significance | Transplant Consideration |
|---|---|---|---|
| 6–9 | ~2% | Compensated disease; low short-term risk | Generally too well for transplant benefit; monitor |
| 10–15 | ~6% | Mild-to-moderate dysfunction | List if trajectory worsening; transplant benefit uncertain at lower end |
| 16–19 | ~10–15% | Moderate dysfunction; decompensation likely | Clear transplant benefit; active listing recommended |
| 20–29 | ~20–40% | Severe dysfunction; high short-term risk | High priority; frequent MELD recertification (every 7 days if ≥ 25) |
| 30–39 | ~50–75% | Critical; multi-organ compromise | Highest priority; assess transplant candidacy urgently |
| 40 | > 70% | Maximum score; imminent mortality risk | Status 1A may apply if meeting acute liver failure criteria |
The “transplant benefit threshold” is generally considered to be a MELD of approximately 15. Below this level, the surgical risk of transplantation may outweigh the mortality risk of remaining on the waiting list. Above 15, transplant confers a clear survival benefit. However, individual factors — including HCC exception points, refractory complications, and quality of life — may justify listing at lower MELD scores.
Aetiologies & MELD Performance by Disease
The MELD score performs differently across the major aetiologies of end-stage liver disease. Some conditions are well-captured by the biochemical variables (bilirubin, INR, creatinine, sodium), while others cause significant morbidity and mortality that the MELD systematically underestimates. Understanding these disease-specific nuances is critical for transplant listing decisions.
ALD is the most common indication for liver transplantation in many countries. The MELD score generally performs well in this population, as ALD causes progressive hepatocellular failure with rising bilirubin, coagulopathy, and often hepatorenal syndrome — all captured by MELD components. Patients with severe alcoholic hepatitis may have very high MELD scores (30–40) reflecting acute-on-chronic liver failure.
The key consideration in ALD is the requirement for a period of documented alcohol abstinence (traditionally 6 months, though early transplant for alcoholic hepatitis is increasingly accepted at select centres). MELD alone does not capture relapse risk, psychosocial factors, or the potential for recovery with abstinence — all of which influence listing decisions beyond the numerical score.
MASLD (formerly NAFLD/NASH) is the fastest-growing indication for liver transplantation worldwide. The MELD score captures hepatic synthetic dysfunction and renal impairment well in advanced MASLD cirrhosis. However, MASLD patients frequently have significant cardiovascular comorbidities (coronary artery disease, heart failure, obesity) that affect transplant candidacy and post-transplant survival but are not reflected in the MELD score.
Patients with MASLD-related cirrhosis may also develop hepatocellular carcinoma, which is an indication for MELD exception points. Cardiovascular risk assessment (coronary angiography, dobutamine stress echocardiography) is an essential part of the transplant evaluation in this population, independent of the MELD score.
HCC represents the most important limitation of the MELD score. Many patients with early HCC have well-compensated cirrhosis and low MELD scores (6–12), yet they face significant mortality risk from tumour progression if transplantation is delayed. Without MELD exception points, these patients would be systematically disadvantaged in the allocation system.
The UNOS/OPTN system addresses this through standardised exception points for patients meeting the Milan criteria (single tumour ≤ 5 cm or up to 3 tumours each ≤ 3 cm, no vascular invasion, no extrahepatic spread). Exception MELD points are assigned at a level that provides reasonable transplant access without disadvantaging non-HCC candidates. The specific exception policies are periodically updated — clinicians should refer to current OPTN policy for the latest criteria.
Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) present unique challenges for MELD scoring. Both conditions cause elevated bilirubin, which increases the MELD score, but the trajectory and clinical significance of hyperbilirubinaemia differ from hepatocellular causes. PSC patients often develop recurrent cholangitis, pruritus, and cholangiocarcinoma — complications that severely impair quality of life but may not be reflected in the MELD score.
Cholangiocarcinoma arising in PSC is particularly problematic: it is often a contraindication to standard transplantation, yet specialised protocols (neoadjuvant chemoradiation followed by transplant) exist at selected centres. These patients may qualify for MELD exception points under specific institutional protocols.
Acute liver failure (ALF) — defined as severe hepatic dysfunction with coagulopathy and encephalopathy in patients without pre-existing liver disease — is managed outside the standard MELD allocation system. In the United States, patients meeting ALF criteria receive Status 1A listing, which confers the highest transplant priority regardless of MELD score.
The MELD score may underestimate severity in early ALF (before creatinine rises) or overestimate it in conditions where spontaneous recovery is expected (e.g., paracetamol overdose with declining transaminases). The King’s College Criteria and the Clichy criteria remain the most widely used prognostic tools for determining transplant need in ALF, rather than the MELD score.
Special Populations & MELD Exceptions
Several clinical scenarios require MELD exception points or alternative scoring approaches because the standard MELD formula systematically underestimates disease severity or mortality risk in these populations.
Women have lower muscle mass and consequently lower serum creatinine at equivalent levels of renal dysfunction. Because creatinine is heavily weighted in the MELD formula, this results in systematically lower MELD scores for women — contributing to longer waiting times and higher waitlist mortality. MELD 3.0 partially addresses this by adding 1.33 points for female sex and incorporating albumin, which better captures nutritional and hepatic synthetic status.
Hepatorenal syndrome (HRS) causes rapidly rising creatinine, which dramatically increases the MELD score. While this appropriately prioritises patients with HRS (who have very high short-term mortality), it can create a paradox: a patient with HRS may receive a higher MELD than a patient with equivalent liver disease severity but preserved renal function. Dialysis further complicates scoring by setting creatinine to a fixed value.
Hepatopulmonary syndrome (HPS) causes progressive hypoxaemia due to intrapulmonary vascular dilatation. These patients may have excellent hepatic synthetic function and low MELD scores despite severe, life-threatening gas exchange impairment. MELD exception points are available for patients with PaO₂ < 60 mmHg. Transplantation is the only curative treatment, and HPS typically resolves post-transplant.
Children under 12 years use the Paediatric End-Stage Liver Disease (PELD) score rather than MELD. PELD includes albumin, bilirubin, INR, growth failure, and age < 1 year. Adolescents 12–17 may use MELD. The PELD and MELD scales were intentionally calibrated to be equivalent in organ allocation priority, though practical disparities exist due to the smaller paediatric donor pool.
MELD Exception Conditions: In addition to HCC and HPS, MELD exception points may be granted for portopulmonary hypertension, familial amyloid polyneuropathy, primary hyperoxaluria, cystic fibrosis, and hilar cholangiocarcinoma (at approved protocol centres). Each exception follows specific OPTN policies with defined criteria for eligibility and point assignment. Refer to current OPTN/UNOS policy for the latest exception guidance.
Common Pitfalls & Limitations
The MELD score has transformed liver transplant allocation, but it has well-recognised limitations that can lead to both underestimation and overestimation of disease severity.
MELD components — particularly INR and creatinine — can fluctuate significantly over short time periods. An INR drawn during a gastrointestinal bleed may be substantially higher than a steady-state value. Creatinine may be transiently elevated from dehydration and normalise rapidly with fluid resuscitation. A single MELD calculation represents a snapshot, and the timing of laboratory draws can meaningfully change the score.
INR standardisation is an additional concern: despite the intent of the INR system to normalise prothrombin time results across laboratories, significant inter-laboratory variability persists — particularly at higher INR values. A patient’s INR may differ by 0.5–1.0 units between laboratories using different thromboplastin reagents, potentially changing the MELD by 2–3 points.
Serum creatinine systematically underestimates renal dysfunction in cirrhotic patients for several reasons: reduced hepatic creatine synthesis, decreased muscle mass from sarcopenia and malnutrition, and haemodilution from hypervolaemia. A “normal” creatinine of 1.0 mg/dL in a cachectic cirrhotic patient may correspond to a GFR as low as 30–40 mL/min.
This means the MELD score underestimates disease severity in patients with significant renal impairment who still have a “normal” creatinine. Cystatin C–based GFR estimation may provide a more accurate assessment of renal function in cirrhosis and has been proposed as a replacement for creatinine in future MELD iterations, though it has not yet been adopted.
The MELD score measures hepatic synthetic function (bilirubin, INR), renal function (creatinine), and hyponatraemia — but it does not capture several complications that cause significant morbidity and mortality in cirrhosis. Refractory ascites requiring frequent paracentesis, recurrent hepatic encephalopathy, spontaneous bacterial peritonitis, sarcopenia, and severe fatigue/debility are all absent from the formula.
A patient with well-compensated biochemistry (MELD 8) but refractory ascites requiring weekly paracentesis and recurrent hospitalisations for encephalopathy may have a worse quality of life and higher mortality risk than their MELD score suggests. These “MELD-discordant” patients represent an ongoing challenge in transplant allocation equity.
When a patient receives dialysis (≥ 2 sessions per week or CVVHD for ≥ 24 hours), the MELD formula sets creatinine to 4.0 mg/dL (MELD-Na) or 3.0 mg/dL (MELD 3.0) regardless of the actual measured creatinine. This can substantially inflate the MELD score. While this is appropriate for patients with true hepatorenal syndrome requiring dialysis, it can be problematic when dialysis is initiated for volume management rather than intrinsic renal failure.
There have been concerns about “gaming” the MELD system by initiating dialysis to increase the score. OPTN policies have been updated to require documentation that dialysis is medically indicated, and centres are audited for appropriateness. Clinicians should ensure dialysis is genuinely required, not strategically deployed to increase transplant priority.
Patients taking warfarin or other vitamin K antagonists will have an elevated INR that reflects the anticoagulant effect rather than hepatic synthetic dysfunction. This artificially inflates the MELD score. Current OPTN policy does not adjust for anticoagulant use, though some centres document the indication for anticoagulation and the degree of INR elevation attributable to it.
Direct-acting oral anticoagulants (DOACs) do not affect the INR significantly and therefore do not create this scoring artefact. For patients on warfarin who are being evaluated for transplant listing, some clinicians advocate measuring the INR after warfarin discontinuation (with bridging anticoagulation if indicated) to obtain a true measure of hepatic synthetic function.
The MELD score was designed to predict short-term mortality without transplantation — it is not a measure of post-transplant outcome. A patient with a high MELD may have a higher perioperative risk but a greater net survival benefit from transplantation. Conversely, the “transplant benefit” model (which considers both waitlist and post-transplant mortality) is increasingly used to inform allocation alongside the MELD score.
Quick Reference Summary
(both MELD-Na & 3.0)
threshold (general)
time horizon
sex adjustment
| Version | Variables | Adopted | Key Improvement |
|---|---|---|---|
| Original MELD | Bilirubin, INR, Creatinine | UNOS 2002 | Replaced time-based allocation |
| MELD-Na | + Serum Sodium | UNOS 2016 | Better captures hyponatraemia-related mortality |
| MELD 3.0 | + Sex, Albumin | OPTN 2023 | Addresses sex-based disparity; better calibration |
The Golden Rule: MELD predicts waitlist mortality — it does not measure quality of life, post-transplant outcome, or the full burden of liver disease. Patients with “MELD-discordant” conditions (refractory ascites, recurrent encephalopathy, HCC, hepatopulmonary syndrome) may warrant transplant evaluation even at lower MELD scores. Always consider the complete clinical picture beyond the number.
Disclaimer & References
For Educational Purposes Only. This calculator and the accompanying clinical information are intended as educational tools for healthcare professionals. They do not replace clinical judgement. Results should be interpreted in the full clinical context. Lab reference ranges vary by institution — verify with your own laboratory. Drug dosages should be confirmed against current prescribing information.
References
- Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–470. DOI: 10.1053/jhep.2001.22172
- Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91–96. DOI: 10.1053/gast.2003.50016
- Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359(10):1018–1026. DOI: 10.1056/NEJMoa0801209
- Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021;161(6):1887–1895.e4. DOI: 10.1053/j.gastro.2021.08.050
- Biggins SW, Kim WR, Terrault NA, et al. Evidence-Based Incorporation of Serum Sodium Concentration Into MELD. Gastroenterology. 2006;130(6):1652–1660. DOI: 10.1053/j.gastro.2006.02.010
- Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. J Hepatol. 2011;54(6):1297–1306. DOI: 10.1016/j.jhep.2010.11.008
- Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864–871. DOI: 10.1053/he.2000.5852
- Nagai S, Chau LC, Schilke RE, et al. Effects of Allocating Livers for Transplantation Based on Model for End-Stage Liver Disease–Sodium on Waitlist Outcomes. Gastroenterology. 2018;155(5):1451–1462.e3. DOI: 10.1053/j.gastro.2018.07.025
- Lai JC, Tandon P, Bernal W, et al. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(3):1611–1644. DOI: 10.1002/hep.32049